Inmaculada Puertas

Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease

Lídia Sabater, Mar Guasp, Raquel Ruiz García, Laura Naranjo Rondán et autres

BACKGROUND AND OBJECTIVES: Anti-IgLON5 disease is characterized by substantial clinical heterogeneity and variable outcomes. We investigated the associations of clinical features as well as serum neurofilament light chain (NfL), phosphorylated tau (p-tau), IgG4 levels, and the HLA-DRB110:01∼DQB105:01 haplotype with disease presentation and …

es, it, dk, br, fr, at, de, us, ca, be (code pays fourni par la source)

Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis Patients

Gabriel Torres Iglesias, Ana Martínez‐Feito, Laura Otero‐Ortega, MariPaz López-Molina et autres

BACKGROUND: Immunological monitoring in multiple sclerosis (MS) patients treated with disease-modifying drugs may help predict infectious complications and guide treatment. The main objective of this study was to evaluate whether anti-CD20 treatments in MS patients induce immunodeficiency and whether certain immunological parameters …

es (code pays fourni par la source)

Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis

MariPaz López-Molina, Gabriel Torres Iglesias, Gonzalo Sáenz de Santa María-Diez, Jaime Valentín‐Quiroga et autres

Introduction Although numerous disease-modifying treatments have been introduced for multiple sclerosis (MS), approximately 25% of patients experience therapeutic failure. This underscores the urgent need for reliable, minimally invasive biomarkers to predict treatment response at early stages. This study aimed to investigate 22 …

es (code pays fourni par la source)

Extracellular Vesicles as Novel Biomarkers for Tumor Association in Intermediate-Risk Paraneoplastic Neurologic Syndromes

Gabriel Torres Iglesias, Alba Chavarría‐Miranda, MariPaz López-Molina, Carlos del Fresno et autres

BACKGROUND AND OBJECTIVES: Paraneoplastic neurologic syndromes (PNS) are cancer-related neurologic disorders caused by an autoimmune response targeting both the tumor and the nervous system. Identifying new biomarkers for early cancer detection could improve treatment outcomes. Tumor-derived cells release extracellular vesicles (EVs) carrying …

es (code pays fourni par la source)

Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease

Thomas Grüter, Carles Gaig, Yvette S. Crijnen, Maarten J. Titulaer et autres

Importance: Anti-IgLON5 disease is an autoimmune encephalopathy that often leads to severe disability or death. The efficacy of immunotherapy remains unknown. Objective: To investigate whether early immunotherapy is associated with disability and death in anti-IgLON5 disease. Design, Setting, and Participants: This retrospective, …

de, es, nl, at, fr (code pays fourni par la source)

Extracellular Vesicle-Derived MicroRNAs as a Biomarker for Therapeutic Response in Multiple Sclerosis

Gabriel Torres-Iglesias, MariPaz López-Molina, Rubén Ayala-Suárez, Beatriz Egido et autres

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is the leading cause of neurologic disability in young adults worldwide. Despite the development of 20 disease-modifying treatments (DMTs) aimed at reducing disability, approximately 30% of patients experience therapeutic failure. Identifying early biomarkers for therapeutic response …

es (code pays fourni par la source)

20328. ALTERACIONES EN LA EXPRESIÓN DE MOLÉCULAS REGULADORAS EN CÉLULAS B: IMPLICACIONES EN LA PROGRESIÓN DE LA DISCAPACIDAD EN ESCLEROSIS MÚLTIPLE

M. López Molina, Gabriel Torres Iglesias, Laurence Vidal, J. Pozo Novoa et autres

20236. IDENTIFICACIÓN DE CANDIDATOS A TRATAMIENTO DE ALTA EFICACIA EN ESCLEROSIS MÚLTIPLE A TRAVÉS DE LA CARACTERIZACIÓN INMUNOFENOTÍPICA DEL SISTEMA INMUNITARIO

L. Vidal Guerrero, Gabriel Torres Iglesias, M. López Molina, Rafael Gallego et autres

20324. EXPRESIÓN DE MOLÉCULAS DE PUNTOS DE CONTROL INMUNITARIO COMO BIOMARCADORES DE RESPUESTA AL TRATAMIENTO EN PACIENTES CON ESCLEROSIS MÚLTIPLE

M. López Molina, Gabriel Torres Iglesias, Laurence Vidal, Rosa Ma Prieto Gallego et autres

20967. TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE CON OCRELIZUMAB Y RITUXIMAB: MONITORIZACIÓN INMUNOLÓGICA A LARGO PLAZO PARA EVALUAR EL RIESGO DE INFECCIONES Y LA RESPUESTA AL TRATAMIENTO

Gabriel Torres Iglesias, Ana Martínez‐Feito, Laura Otero‐Ortega, M. López Molina et autres

20811. MICROARN CONTENIDOS EN VESÍCULAS EXTRACELULARES CIRCULANTES COMO BIOMARCADORES MOLECULARES DE RESPUESTA AL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE

Gabriel Torres Iglesias, Martín Molina, Rosa Ayala, Luis Botella et autres

Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis

Gabriel Torres Iglesias, MariPaz López-Molina, Lucía Botella, Fernando Laso-García et autres

Multiple sclerosis (MS) remains the leading cause of neurological disability among young adults worldwide, underscoring the urgent need to define the best therapeutic strategy. Recent advances in proteomics have deepened our understanding of treatment mechanisms and revealed promising biomarkers for predicting therapeutic …

es (code pays fourni par la source)